JHPCY — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2071868 ·
China
Last close
$13.60
Market Cap
$1.76B
52W High
$18.00
52W Low
$13.60
ADV30
554
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,140,565,321 | 7,049,616,182 | 2,579,989,309 | 2,282,268,233 | 71,293,862,441 | 40,526,883,023 | 7,146,776,163 |
| Dec 2025 | 8,441,334,265 | 7,274,119,633 | 2,330,380,135 | 1,959,885,274 | 69,867,315,774 | 40,955,482,468 | 8,070,492,359 |
| Jun 2025 | 8,555,582,506 | 7,509,282,853 | 2,807,885,640 | 2,576,050,864 | 62,893,517,149 | 36,121,847,259 | 3,863,719,109 |
| Mar 2025 | 7,205,611,123 | 6,136,948,606 | 2,018,181,174 | 1,874,055,520 | 51,292,781,691 | 24,085,707,596 | 3,743,012,633 |
Balance + Analyst (yfinance extras)
Retained Earnings
$42,455,623,061
Inventory
$2,886,056,361
Receivables
—
ST Investments
$108,916,478
EBIT TTM
$9,917,521,709
Pretax Income TTM
$9,903,414,008
Interest Exp TTM
$14,107,702
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$5,597,861,888
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
129,098,800
Trailing EPS
$0.36
Book Value
$2.80
ROE
14.5%
ROA
8.8%
Div Yield
0.43%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,629,416,194 | 8,596,411,752 | 7,711,054,812 | 69,867,315,774 | 8,070,492,359 | — | 11,235,378,131 |
| Dec 2024 | 27,984,605,342 | 6,803,132,569 | 6,336,527,015 | 50,135,645,304 | 4,045,394,571 | — | 7,422,753,039 |
| Dec 2023 | 22,819,784,741 | 4,625,728,312 | 4,302,435,930 | 43,784,506,636 | 2,751,420,194 | — | 7,643,665,075 |
| Dec 2022 | 21,275,270,682 | 3,344,720,696 | 3,906,375,067 | 42,370,875,898 | 3,957,967,303 | — | 1,265,264,632 |
News headlines (Yahoo Finance, 1h cache)
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
2026-06-05 23:32 · Yahoo
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
2026-06-01 05:51 · Yahoo
Kailera’s three-pronged obesity shot shows promise in early trial
2026-05-27 11:45 · Yahoo
A Look At Bristol Myers Squibb (BMY) Valuation After Major Hengrui Collaboration Announcement
2026-05-15 09:15 · Yahoo
Bristol-Myers Strikes $15.2 Billion China Drug Deal
2026-05-13 12:57 · Yahoo
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
2026-05-13 11:30 · Yahoo
BMS and Hengrui forge $15.2bn alliance for early-stage drugs
2026-05-12 15:10 · Yahoo
Bristol Myers Squibb signs $15.2B licensing deal with Hengrui
2026-05-12 13:48 · Yahoo
Bristol Myers Squibb Expands Pipeline With Hengrui Multi Billion Drug Alliance
2026-05-12 11:15 · Yahoo
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
2026-05-12 08:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.